Back to Results
First PageMeta Content
Biology / Peptide hormones / Recombinant proteins / Medicine / Insulin analog / Insulin therapy / Insulin aspart / Insulin pump / Novo Nordisk / Diabetes / Endocrine system / Eli Lilly and Company


PREFERRED STEP THERAPY POLICY Insulin (Rapid-Acting) Preferred Step Therapy Program To Initiate a Coverage Review, Call[removed]DRUGS AFFECTED: Apidra® (insulin glulisine [rDNA origin] injection – Sanofi Aventi
Add to Reading List

Document Date: 2014-05-05 10:56:54

Open Document

File Size: 95,91 KB

Share Result on Facebook

City

Princeton / Indianapolis / Bridgewater / /

Company

Eli Lilly / Type / Sanofi Aventis / Eli Lilly and Company / Novo Nordisk Pharmaceuticals Inc. / Sanofi-Aventis U.S. LLC. / Arnqvist HF. / Russell / Novo Nordisk / /

IndustryTerm

individual products / insulin devices / diabetes management algorithm / Diabetes Care / /

MedicalCondition

postprandial hyperglycemia / comprehensive diabetes / Pediatr Diabetes / non-insulin-dependent diabetes mellitus / hyperglycemia / diabetes / Type 1 diabetes mellitus / hypoglycemia / /

MedicalTreatment

Drug Therapy / insulin therapy / /

Organization

ADA/European Association for the Study of Diabetes / European Association for the Study of Diabetes / American Association for Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing / American Diabetes Association / American Association of Clinical Endocrinologists / /

Person

Arch Intern / Ann Intern / /

/

Product

NovoLog / NovoLog Mix / regular insulin / Humalog / Apidra / /

RadioStation

Mix 75 / /

Technology

diabetes management algorithm / /

SocialTag